Paradigm Biocapital Advisors LP Bolsters Position in Y-mAbs Therapeutics Inc

YMAB Stock  USD 11.92  0.04  0.34%   
About 63% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Recent Acquisition by Paradigm Biocapital Advisors LP On September 30, 2024, Paradigm Biocapital Advisors LP made a sign

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Y MAbs Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Y MAbs Fundamental Analysis

We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash And Equivalents

Cash And Equivalents Comparative Analysis

Y MAbs is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Y mAbs Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.

Peers

Y MAbs Related Equities

PASGPassage Bio   68.66   
0%
100.0%
ARQTArcutis Biotherapeutics   11.36   
0%
16.0%
CCCCC4 Therapeutics   8.59   
0%
12.0%
BLUEBluebird Bio   7.89   
0%
11.0%
GBIOGeneration Bio   6.29   
0%
9.0%
MRSNMersana Therapeutics   4.11   
0%
5.0%
BDTXBlack Diamond   3.11   
0%
4.0%
EWTXEdgewise Therapeutics   2.48   
0%
3.0%
DAWNDay One   1.53   
0%
2.0%
SNDXSyndax Pharmaceuticals   1.27   
0%
1.0%
TVTXTravere Therapeutics   0.59   
0%
1.0%
PCVXVaxcyte   0.38   
0%
1.0%
MRUSMerus BV   0.29   
1.0%
0%
ZNTLZentalis Pharmaceuticals   0.55   
1.0%
0%
MIRMMirum Pharmaceuticals   0.92   
1.0%
0%
KRONKronos Bio   1.04   
1.0%
0%
RVMDRevolution Medicines   1.25   
1.0%
0%
STROSutro Biopharma   1.49   
2.0%
0%
ERASErasca   2.05   
2.0%
0%
LRMRLarimar Therapeutics   4.67   
6.0%
0%

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum